Holen Sie sich die Stockscreener-App
0.79
7.06%
-0.06
Handel nachbörslich:
.79
Schlusskurs vom Vortag:
$0.85
Offen:
$0.86
24-Stunden-Volumen:
346.16K
Relative Volume:
0.56
Marktkapitalisierung:
$43.85M
Einnahmen:
$2.91M
Nettoeinkommen (Verlust:
$-15.61M
KGV:
-2.0573
EPS:
-0.384
Netto-Cashflow:
$-14.50M
1W Leistung:
+1.28%
1M Leistung:
+30.13%
6M Leistung:
-33.61%
1J Leistung:
+3.93%
1-Tages-Spanne:
$0.7805
$0.8607
1-Wochen-Bereich:
$0.72
$0.90
52-Wochen-Spanne:
$0.48
$1.57
Icecure Medical Ltd Stock (ICCM) Company Profile
Firmenname
Icecure Medical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Icecure Medical Ltd Aktie (ICCM) Neueste Nachrichten
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 - BioSpace
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - Marketscreener.com
Independent Study Results in Japan Demonstrate Zero (0%) Breast - GuruFocus.com
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 - GuruFocus.com
Globus Medical (NYSE:GMED) & IceCure Medical (NASDAQ:ICCM) Head-To-Head Contrast - Defense World
IceCure receives US patent allowance for cryoablation system - Investing.com
IceCure receives US patent allowance for cryoablation system By Investing.com - Investing.com Australia
IceCure Announces FDA Advisory Panel Meeting Date for Marketing - GuruFocus.com
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System - Marketscreener.com
Analytical Overview: Icecure Medical Ltd (ICCM)’s Ratios Tell a Financial Story - The Dwinnex
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablati - GuruFocus.com
Icecure Medical Ltd (ICCM) shows promising results - US Post News
Ratios in Focus: Analyzing Icecure Medical Ltd (ICCM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference - StreetInsider.com
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com Australia
Ex-ad industry employees launch a new digital agency 'itch' - afaqs!
IceCure reports high success rate in breast cancer trial - Investing.com India
Why Is Interactive Strength Stock Surging Today? - Benzinga
InCred's Aditya Sood Reveals Key Factors Behind Selecting Indraprastha Medical From Hospital Sector - Business Today
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96 - StreetInsider.com
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PR Newswire
The time has not yet come to remove your chips from the table: Icecure Medical Ltd (ICCM) - SETE News
What will the future hold for Icecure Medical Ltd (NASDAQ:ICCM) stock? - US Post News
FDA AdComm to discuss IceCure's ProSense on Nov. 7 - MSN
Study: Liquid Nitrogen-Based Cryoablation Safe for Treating Treating Tumors of the Lung, Bone and Soft Tissues - Imaging Technology News
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues - StockTitan
H.C. Wainwright maintains Buy rating on IceCure Medical stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy rating on IceCure Medical stock - Investing.com India
Icecure Medical Ltd (ICCM) deserves closer scrutiny - US Post News
IceCure seeks FDA nod for breast cancer treatment - Investing.com
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 - PR Newswire
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences - PR Newswire
Icecure Medical Ltd (ICCM) can make a big difference with a little luck - SETE News
Icecure Medical Ltd (ICCM) produces promising results - US Post News
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Malaysian Reserve
IceCure expands patent portfolio with USPTO allowance - Investing.com
IceCure Medical Strengthens Patent Portfolio - TipRanks
IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com India
IceCure Medical stock target cut, retains buy rating on Q2 results By Investing.com - Investing.com South Africa
IceCure Medical Ltd (NASDAQ:ICCM) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: IceCure Medical reports growth and upcoming FDA panel - Investing.com India
Earnings call: IceCure Medical reports growth and upcoming FDA panel By Investing.com - Investing.com Australia
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates - MSN
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Malaysian Reserve
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 - PR Newswire
Finanzdaten der Icecure Medical Ltd-Aktie (ICCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):